GlycoVaxyn is a privately-funded company developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, proprietary in vivoglycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a biological process that circumvents many of the challenges and uncertainties involved in currently/chemical used methods. In addition to the clinical stage Shigella vaccines, lead programs in preclinical stage are aimed at the prevention of hospital acquired Staphylococcusaureus infections, as well as pneumococcal invasive diseases. GlycoVaxyn has established collaborations with GlaxoSmithKline (GSK) and Janssen Pharmaceuticals. The company was founded in 2004 as a spin-out from the Federal Institute of Technology in Zurich (ETHZ) and is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners as well as GSK.
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | Andera Par... | anderapart... |
Mentions in press and media 6
| Date | Title | Description | Source |
| 25.01.2016 | Switzerland “the best country for starting a company” | Google will continue to develop in Zurich Google has created over 1600 jobs since its existence i... | startuptic... |
| 02.07.2014 | Vaccine from GlycoVaxyn enters clinical phase | The first-in-human clinical study includes 180 women affected by recurrent UTI. It is a multicente... | startuptic... |
| 09.01.2013 | GlycoVaxyn Enters Collaboration with Janssen | GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Janssen Ph... | startuptic... |
| 28.09.2012 | ProteoMediX Winner of the Life Sciences Prize 2012 | The prize of CHF 10'000, awarded today for the ninth time, is under the patronage of the Swiss Biote... | startuptic... |
| 19.06.2012 | Index Ventures raises EUR350m for new early stage technology... | Normal 0 21 false false false DE-CH X-NONE X-NONE The new fund of Index Ventures will invest in se... | startuptic... |
| 21.07.2007 | GlycoVaxyn pulls in $9.3M for conjugated vaccines | Zurich’s GlycoVaxyn, a biotech developing new “conjugated vaccines”, raised a $9.3 million first fun... | venturebea... |